全文获取类型
收费全文 | 20405篇 |
免费 | 1563篇 |
国内免费 | 103篇 |
专业分类
耳鼻咽喉 | 189篇 |
儿科学 | 397篇 |
妇产科学 | 351篇 |
基础医学 | 2625篇 |
口腔科学 | 218篇 |
临床医学 | 1919篇 |
内科学 | 5152篇 |
皮肤病学 | 424篇 |
神经病学 | 2182篇 |
特种医学 | 1097篇 |
外科学 | 3285篇 |
综合类 | 137篇 |
一般理论 | 6篇 |
预防医学 | 1031篇 |
眼科学 | 188篇 |
药学 | 1318篇 |
中国医学 | 22篇 |
肿瘤学 | 1530篇 |
出版年
2023年 | 117篇 |
2022年 | 191篇 |
2021年 | 522篇 |
2020年 | 255篇 |
2019年 | 533篇 |
2018年 | 626篇 |
2017年 | 421篇 |
2016年 | 433篇 |
2015年 | 542篇 |
2014年 | 806篇 |
2013年 | 951篇 |
2012年 | 1515篇 |
2011年 | 1546篇 |
2010年 | 875篇 |
2009年 | 849篇 |
2008年 | 1297篇 |
2007年 | 1279篇 |
2006年 | 1287篇 |
2005年 | 1174篇 |
2004年 | 1062篇 |
2003年 | 929篇 |
2002年 | 895篇 |
2001年 | 327篇 |
2000年 | 291篇 |
1999年 | 268篇 |
1998年 | 188篇 |
1997年 | 202篇 |
1996年 | 175篇 |
1995年 | 130篇 |
1994年 | 131篇 |
1993年 | 90篇 |
1992年 | 162篇 |
1991年 | 158篇 |
1990年 | 157篇 |
1989年 | 133篇 |
1988年 | 136篇 |
1987年 | 149篇 |
1986年 | 118篇 |
1985年 | 119篇 |
1984年 | 83篇 |
1983年 | 70篇 |
1982年 | 68篇 |
1981年 | 49篇 |
1977年 | 47篇 |
1975年 | 53篇 |
1974年 | 55篇 |
1972年 | 51篇 |
1971年 | 52篇 |
1970年 | 50篇 |
1969年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
25.
Ladenstein Ruth; Pearce Rachel; Hartmann Olivier; Patte Catherine; Goldstone Tony; Philip Thierry 《Blood》1997,90(8):2921-2930
26.
27.
Marc Ziegler Alexandre Castro-Caldas Susanna Del Signore Olivier Rascol 《Movement disorders》2003,18(4):418-425
Piribedil is a non-ergot D2/D3 agonist with a significant antagonist action on alpha2A and alpha2C adrenergic receptor subtypes. This double-blind placebo-controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's disease (PD) in nonfluctuating patients insufficiently controlled by a stable daily dose of levodopa (L-dopa). Efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) III score as primary criterion over 4 months. A second comparison was planned at 6 months, after possible adjustment of L-dopa. At 4 months, the rate of response, defined as a 30% decrease from baseline on UPDRS III score, was significantly greater with piribedil compared with placebo (56.4% vs. 37.7%; P = 0.040). At 6 months, the better efficacy of piribedil was maintained (61.8% of responders vs. 39.6% on placebo; P = 0.020). The difference between groups on UPDRS III change from baseline reached statistical significance only at 6 months: -10.0 points in the piribedil group vs. -6.7 points in the placebo group (P = 0.037). Secondary end-points were not significantly different. The most frequently reported adverse events were gastrointestinal symptoms (27 of 61 patients in the piribedil group vs. 13 of 54 patients in the placebo group). In conclusion, a 6-month oral administration of 150 mg/day piribedil in combination with L-dopa is well tolerated, except for minor gastrointestinal symptoms at the beginning of the treatment and significantly improves motor symptoms compared with placebo in PD nonfluctuating patients. 相似文献
28.
29.
The kinetics of insulin-mediated glucose uptake (IMGU) and non-insulin-mediated glucose uptake (NIMGU) in humans have not been well defined. We used the glucose-clamp technique to measure rates of whole-body and leg muscle glucose uptake in six healthy lean men during hyperinsulinemia (approximately 460 pM) to study IMGU and during somatostatin-induced insulinopenia to study NIMGU at four glucose levels (4.5, 9, 12, and 21 mM). To measure leg glucose uptake, the femoral artery and vein were catheterized, and blood flow was measured by thermodilution (leg glucose uptake = arteriovenous glucose difference [A-VG] x blood flow). With this approach, we found that, during hyperinsulinemia, both whole-body and leg glucose uptake increased in a curvilinear fashion at every glucose level, the highest glucose uptake values obtained being 139 +/- 17 mumol.kg-1.min-1 and 3656 +/- 931 mumol.min-1.leg-1, respectively. Leg blood flow increased twofold from 6.0 +/- 1.7 to 11.7 +/- 3.1 dl/min (P less than 0.01) over the range of glucose and was correlated with whole-body glucose uptake (r = 0.55, P less than 0.005). Leg muscle glucose extraction, independent of changes in blood flow, which is reflected by the A-VG, saturated over the range of glucose (1.28 +/- 0.12, 2.22 +/- 0.30, 2.92 +/- 0.42, 3.02 +/- 0.41 mM, NS between last 2 values) with a half-maximal effective glucose concentration (EG50) of 5.3 +/- 0.4 mM.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
30.